---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-003316"
form_type: "8-K"
ticker: "SMTI"
cik: "0000714256"
company_name: "Sanara MedTech Inc."
filed_at: "2026-01-23T23:59:59+00:00"
generated_at: "2026-05-16T08:36:55.660451+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sanara MedTech reports preliminary FY 2025 revenue ~$103M, guides FY 2026 revenue $116M-$121M

## Summary
- Q4 2025 net revenue expected $27.2M-$27.7M, up 3-5% YoY; excluding $1.8M BIASURGE sales in Q4'24, growth 11-13%.
- FY 2025 net revenue expected $102.7M-$103.2M, ~19% YoY growth; excluding $1.8M BIASURGE, growth 21-22%.
- FY 2026 guidance: net revenue $116M-$121M, growth 13-17% from 2025 midpoint.
- Cash $16.6M, long-term debt $46.0M at Dec 31, 2025 (vs $15.9M cash, $30.7M debt a year earlier).
- BIASURGE receives Vizient Innovative Technology contract; OsStic launch planned Q1 2027 pending FDA clearance.

## SEC filing metadata
- accession: 0001493152-26-003316
- form_type: 8-K
- ticker: SMTI
- cik: 0000714256
- company_name: Sanara MedTech Inc.
- filed_at: 2026-01-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/714256/000149315226003316/0001493152-26-003316-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/714256/000149315226003316/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-003316
- JSON: https://secwatch.observer/filing/0001493152-26-003316.json
- Plain text: https://secwatch.observer/filing/0001493152-26-003316.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.